Abstract: A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.

Abstract: A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.

Abstract: An object of the present invention is to provide a monoclonal antibody which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The present invention relates to a monoclonal antibody which binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15), or an antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment.

Abstract: A well has a pair of side surfaces, and one of the side surfaces is in contact with a compartment of a first channel with a gas-permeable membrane being interposed therebetween and the other side surface is in contact with a compartment of a second channel with a gas-permeable membrane being interposed therebetween. The well is filled with a liquid cell culture medium, and in such a state, a high-concentration gas and a low-concentration gas, which are different in the concentration of a specific component from each other, are allowed to flow through the first and second channels, respectively, to form a concentration distribution of the specific component in the well.

Abstract: A cell sorter including a well that has a microspace filled with a liquid and having a typical length of 1 mm or less, and that has a bottom surface made of a light-permeable material allowing optical observation of an interior of the microspace; a matrix provided on the bottom surface in the well; a bone fragment placed on the matrix in the well; and osteoclasts placed between the matrix and the bone fragment.

Abstract: Detection probes are provided that are capable of detecting a sequence to be detected containing a mutation even when a sequence not to be detected containing no mutation coexists with the sequence to be detected containing a mutation, which are different only in a single base from each other. At least one oligonucleotide selected from the group consisting of SEQ ID NOs: 2˜16 is used as a probe. Even in a sample containing an abl gene in which a mutation has occurred and an abl gene in which no mutation has occurred, the use of such probes in, for example, Tm analysis allows the mutation to be detected.

Abstract: A cell sorter including a well that has a microspace filled with a liquid and having a typical length of 1 mm or less, and that has a bottom surface made of a light-permeable material allowing optical observation of an interior of the microspace; a matrix provided on the bottom surface in the well; a bone fragment placed on the matrix in the well; and osteoclasts placed between the matrix and the bone fragment.

Abstract: A well has a pair of side surfaces, and one of the side surfaces is in contact with a compartment of a first channel with a gas-permeable membrane being interposed therebetween and the other side surface is in contact with a compartment of a second channel with a gas-permeable membrane being interposed therebetween. The well is filled with a liquid cell culture medium, and in such a state, a high-concentration gas and a low-concentration gas, which are different in the concentration of a specific component from each other, are allowed to flow through the first and second channels, respectively, to form a concentration distribution of the specific component in the well.

Abstract: A method of detecting a mutation is provided that uses Tm analysis and is excellent in detection sensitivity. A detection probe consisting of a polynucleotide complementary to a sequence to be detected containing a detection site that has been mutated and an inhibitory polynucleotide complementary to a sequence not to be detected containing the detection site that is unmutated are added to a sample containing a DNA to be detected in which the detection site has been mutated and a DNA not to be detected in which the detection site is unmutated, so that the detection probe is hybridized with the DNA. Then while the hybridization product between the DNA and the detection probe is heated, a signal variation associated with an increase in temperature is measured, then the signal variation is analyzed, and thereby a Tm value is determined, based on which the presence of the mutation is determined.

Abstract: A probe for detecting a mutation in the JAK2 gene is provided that can detect a target sequence containing a mutation even when the target sequence containing the mutation and a non-target sequence containing no mutation coexist, which are different only in a single base from each other. The probe to be used is an oligonucleotide that is at least one oligonucleotide having a sequence identical to that of a region extending from a cytosine base (C) at position 84 to be considered as the first base to any one of the 17th to 22nd bases in the direction toward the 5? end in exon 12 of the JAK2 gene consisting of the base sequence of SEQ ID NO: 1, with the cytosine base (C) being the 3? end. Even in the case of a sample containing both the JAK2 genes with a mutation that has occurred and without a mutation that has occurred, the use of such a probe in, for example, Tm analysis allows the former mutation to be detected. Preferably, the probe is labeled with a fluorescent dye.

Abstract: Detection probes are provided that are capable of detecting a sequence to be detected containing a mutation even when a sequence not to be detected containing no mutation coexists with the sequence to be detected containing a mutation, which are different only in a single base from each other. At least one oligonucleotide selected from the group consisting of SEQ ID NOs: 2˜16 is used as a probe. Even in a sample containing an abl gene in which a mutation has occurred and an abl gene in which no mutation has occurred, the use of such probes in, for example, Tm analysis allows the mutation to be detected.